Pfizer Presents Results from Two Phase 3 TRUMENBA Studies at the European Society for Paediatric Infectious Diseases Meeting
May 13, 2016 at 06:33 AM EDT
Pfizer Inc. (NYSE: PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal ...